Skip to main content
. 2019 Aug 6;9:707. doi: 10.3389/fonc.2019.00707

Figure 3.

Figure 3

Pathological complete response (pCR) in breast and axilla across the intrinsic subtypes of breast cancer in (A,B) the overall cohort; (C) Patients with HR-positive disease (n = 49); (D) Patients with HR-negative disease (n = 40). HER2-E, HER2-enriched; non-HER2-E, non-HER2-enriched.